OCUL
OCULAR THERAPEUTIX, INCPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 2 to Feb 4 ▼ 2 days of insider sells: $101.4K by 1 insider, avg $8.82
- Feb 12 ▼ 4 insiders sell $1.4M at $9.04
- Feb 20 ▲ 1 insider buy $461.4K at $7.66
- Feb 20 to Feb 23 ▼ 2 days of insider sells: $256.4K by 5 insiders, avg $8.22
- Apr 13 ▲ Ocular Therapeutix presented additional Week 52 post-hoc data from i…
- May 26 ▼ 4 insiders sell $237.8K at $8.20
- Jun 3 ▼ 1 insider sell $122.6K at $8.27
- Jun 4 FDA: Ocular Therapeutix™ to Participate in Clinical Trials at t…
- Aug 24 to Aug 31 ▼ 2 days of insider sells: $333.1K by 5 insiders, avg $10.75
- Oct 2 to Oct 8 ▼ 2 days of insider sells: $234.4K by 3 insiders, avg $7.14
- Oct 12 UBS initiates
- Nov 5 ▼ 1 insider sell $231.7K at $6.55
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider bought $461.4K at an average $7.66. 8 insiders sold $2.9M. Price is 22% below their cost.
- InstitutionsMIXED
Q3 2026: 21 added (0 new), 15 trimmed or exited.
- AnalystsBULLISH
18 of 19 rate it Buy or better. Every target is above the price.
- EstimatesRISING
Current-quarter EPS estimate −$0.388 → −$0.355 over 90 days. 4 up, 0 down in 30 days.
- Short sellersSTEADY
Short interest +0.8% to 29.00M shares. 10.1 days to cover, ≈13.2% of shares.
- TrendDOWNTREND
24% below its 50-day average. New closing low $6.01 on Nov 16.
- SocialQUIET
No Reddit mentions this week. Last mention Nov 10.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| MARSHALL WACE, LLP | DOUBLED | $20.8M |
| UBS Group AG | ADD | $16.3M |
| Invesco Ltd. | ADD | $14.1M |
| RAYMOND JAMES FINANCIAL INC | ADD | $10.3M |
| BNP PARIBAS FINANCIAL MARKETS | DOUBLED | $5.4M |
| BNP Paribas Asset Management Holding S.A. | ADD | $5.0M |
| RENAISSANCE TECHNOLOGIES LLC | ADD | $4.1M |
| Squarepoint Ops LLC | TRIM | $3.7M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
19 analystsPrice is below the lowest target. Median implies +366%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 10, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Oct 19, 2026 | Needham REITERATE | Buy |
| Oct 12, 2026 | UBS INITIATE | Buy |
| Oct 2, 2026 | Chardan Capital MAINTAIN | Buy |
| Sep 29, 2026 | Needham REITERATE | Buy |
| Sep 16, 2026 | Chardan Capital MAINTAIN | Buy |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Sherif Riad Director Nov 6, 2026 | AWARD | 88,000 sh |
Sherif Riad Director Nov 6, 2026 | AWARD | 28,000 sh |
Saroj Namrata Chief Business Officer Nov 5, 2026 | SELL | $231.7K |
Anderman Todd Chief Legal Officer Oct 8, 2026 | SELL | $87.4K |
Heier Jeffrey S. Chief Scientific Officer Oct 2, 2026 | SELL | $76.6K |
Kaiser Peter Chief Development Officer Oct 2, 2026 | SELL | $70.4K |
Notman Donald Chief Operating Officer Aug 31, 2026 | SELL | $11.3K |
Dugel Pravin See Remarks Aug 25, 2026 | GIFT | 50,092 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.35 | -$0.37–-$0.30 | -0.8% | $13.7M |
| Next Q | -$0.38 | -$0.43–-$0.34 | -4.5% | $12.3M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
17 filings · 3 press releases · 2 bullish · 1 bearish · 3 mixed · 11 neutral- NEUTRAL 3Nov 10, 2026
Riad Sherif filed an initial statement of beneficial ownership (Form 3) with Ocular Therapeutix…
This is a routine insider onboarding filing with no trading or ownership implications. No further action warranted.
- NEUTRAL 8-KNov 9, 2026
Ocular Therapeutix elected Riad Sherif, M.D. to its board effective November 6, 2026, and received…
Board changes are routine and carry no immediate trading signal. Monitor for any future 8-K or proxy filing that might indicate a shift in strategic direction or governance, but no action warranted…
- BEARISH PRESS-RELEASENov 9, 2026
Ocular Therapeutix reported Q3 2026 net loss of $(0.42) per share on revenue of $12.9M, missing…
Monitor the AXPAXLI NDA submission in Q4 2026 and the FDA's acceptance decision. The SOL-R interim Week 52 safety analysis in Q4 2026 will be a key catalyst. Cash runway into 2028 provides a long…
- NEUTRAL 144Nov 5, 2026
Namrata Saroj, an officer of Ocular Therapeutix, filed a Form 144 notice of intent to sell 35,370…
The filing indicates an officer intends to sell a modest number of shares. Monitor for actual sale execution on Form 4; the amount is small relative to typical market cap and likely routine…
All OCUL filing & press-release reports (20)
- 3 reportNov 10, 2026
- 8-K reportNov 9, 2026
- PRESS-RELEASE reportNov 9, 2026
- 144 reportNov 5, 2026
- 8-K reportOct 16, 2026
- 144 reportOct 8, 2026
- CLUSTER reportSep 2, 2026
- CLUSTER reportAug 26, 2026
- 8-K reportAug 3, 2026
- PRESS-RELEASE reportJun 17, 2026
- 8-K reportJun 12, 2026
- PRESS-RELEASE reportJun 4, 2026
- CLUSTER reportMay 28, 2026
- PRESS-RELEASE reportMay 5, 2026
- 8-K reportMay 5, 2026
- DEFA14A reportApr 30, 2026
- PRESS-RELEASE reportApr 13, 2026
- PRESS-RELEASE reportApr 1, 2026
- CLUSTER reportFeb 20, 2026
- CLUSTER reportFeb 20, 2026